Dengue Infection in Bangladesh: Transmission, Pathogenesis & Control of Dengue Virus

dc.contributor.authorSinthia, Mahazabin Noor
dc.date.accessioned2023-06-12T03:14:45Z
dc.date.available2023-06-12T03:14:45Z
dc.date.issued23-05-08
dc.description.abstractDengue virus is a human pathogen that infects roughly 390 million people each year, with a quarter of them developing clinical symptoms. Although progress has been made in understanding the biology of dengue fever, there is still no licensed vaccine or antiviral medication available. There is yet no effective antidote for this virus. Patients' treatment is limited to symptomatic relief and Care that is supportive. As a result, the discovery of dengue treatments is critical. This The focus of this review is on the few compounds that have been tested in dengue virus patients: Balapiravir, chloroquine, lovastatin, prednisolone, and celgosivir are some of the drugs used to treat HIV. Balapiravir was expected that the medication would also be effective against DENV because the RdRp of DENV and HCV are comparable. The lessons that these have taught us Clinical trials can be extremely useful in the development of future trials for the dengue virus's next generation inhibitors.
dc.identifier.otherhttp://dspace.daffodilvarsity.edu.bd:8080/handle/123456789/10720
dc.identifier.urihttp://dspace.daffodilvarsity.edu.bd:8080/handle/123456789/10720
dc.language.isoen_US
dc.publisherDaffodil International University
dc.sourceDIU Institutional Repository
dc.subjectDengue Virus
dc.subjectTreatment
dc.subjectClinical Trials
dc.titleDengue Infection in Bangladesh: Transmission, Pathogenesis & Control of Dengue Virus
dc.typeOther

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
23559.pdf.txt
Size:
57.74 KB
Format:
Adobe Portable Document Format

Collections